Outcome of chemotherapy regimens of different combinations for hepatoblastoma
SU Ganglin1,LIU Hongyan2,SUN Yanfeng2,MIAO Lixia2,WANG Jun2,LI Yanshan2,YUAN Hailing2,and LIU Qiuling1,2
SU Ganglin1,LIU Hongyan2,SUN Yanfeng2,MIAO Lixia2,WANG Jun2,LI Yanshan2,YUAN Hailing2,and LIU Qiuling1,2.1.Anhui Medical University, Hefei 230032, China; 2.Department of Pediatrics, General Hospital of Chinese People’s Armed Police Forces, Beijing 100039, China
Abstract：Objective To study the clinical effect of different chemotherapy regimens for children with hepatoblastoma.Methods Clinical data of 23 cases with hepatoblstoma who had been treated in our hospital between August 2007 and February 2016 were summarized. Different chemotherapy regimens were used before and after March 2013. Patients were divided into Group A (12 patients treated between August 2007 and March 2013) and Group B (11 patients treated between March 2013 and February 2016). Chemotherapy combined with surgical treatment was used in both groups. According to the COG stage, patients were stratified into stageⅠ, Ⅱ, Ⅲ, Ⅳ. If feasible, partial hepatectomy(primary or delayed surgery ) was then performed, and four to six final courses were given after AFP was decreased to the normal value. Patients with stage Ⅰ, Ⅱ, Ⅲ in Group A were treated with vincristine , epirubicin and cyclophosphamide while those withstage Ⅳ were treated with cisplatin and epirubicin. In Group B, patients with stage Ⅰ, Ⅱwere treated with cisplatin, vincristine and fluorouracil, and those with stage Ⅲ, Ⅳtreated with cisplatin and epirubicin. Results Complete resection was achieved in each case of hepatoblastoma.By the cutoff date (February 1, 2016), Group B (90.9%) had a higher 1-year PFS rate than group A (41.7%) (P=0.23). Also, group B (90.9%) had a higher 1-year OS rate than group A (58.30%) (P=0.40). Patients in both groups had different degrees of bone marrow suppression after chemotherapy.Conclusion Cisplatin, epirubicin/cisplatin, vincristine and fluorouracil are more effective than vincristine, epirubicin, and cyclophosphamide for children with hepatoblastoma. There is no difference between these chemotherapy regimens, which may be due to the limited amount of data. The side effects of PLA and EPI, and PLA,VCR and 5-FU are reversible and tolerable.
Jon Pritchard, Julia Brown, Elizabeth Shafford, et al. Cisplatin, Doxorubicin, and Delayed Surgery for Childhood Hepatoblastoma: A Successful Approach—Results of the First Prospective Study of the International Society of Pediatric Oncology[J]. J Clin Oncol, 18(22),2000:3819-3828.
[2]
Hishiki T, Matsunaga T, Sasaki F, et al. Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT[J]. Pediatr Surg Int, 2011, 27(1): 1-8.
[3]
Czauderna P, Otte J B, Aronson D C, et al. Guidelines for surgical treatment of hepatoblastoma in the modern era--recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL)[J]. Eur J Cancer, 2005, 41(7): 1031-1036.
[4]
Exelby P R, Filler R M, Grosfeld J L. Liver tumors in children in the particular reference to hepatoblastoma and hepatocellular carcinoma: American Academy of Pediatrics Surgical Section Survey--1974[J]. J Pediatr Surg, 1975, 10(3): 329-337.
[5]
Hiyama E, Ueda Y, Onitake Y, et al. A cisplatin plus pirarubicin-based JPLT2 chemotherapy for hepatoblastoma: experience and future of the Japanese Study Group for Pediatric Liver Tumor (JPLT)[J]. Pediatr Surg Int, 2013, 29(10): 1071-1075.
[6]
Perilongo G, Shafford E, Maibach R, et al. Risk-adapted treatment for childhood hepatoblastoma[J]. European Journal of Cancer, 2004, 40(3): 411-421.
[7]
Zsiros J, Brugieres L, Brock P, et al. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study[J]. Lancet Oncol, 2013, 14(9): 834-842.
[8]
Zsiros J, Maibach R, Shafford E, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study[J]. J Clin Oncol, 2010, 28(15): 2584-2590.
[9]
Ortega J A, Douglass E C, Feusner J H, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children’s Cancer Group and the Pediatric Oncology Group[J]. J Clin Oncol, 2000, 18(14): 2665-2675.
[10]
Maibach R, Roebuck D, Brugieres L, et al. Prognostic stratification for children with hepatoblastoma: the SIOPEL experience[J]. Eur J Cancer, 2012, 48(10): 1543-1549.
[11]
Qiao G L, Li L, Cheng W, et al. Predictors of survival after resection of children with hepatoblastoma: A single Asian center experience[J]. Eur J Surg Oncol, 2014, 40(11): 1533-1539.
[12]
von Schweinitz D, Hecker H, Harms D, et al. Complete resection before development of drug resistance is essential for survival from advanced hepatoblastoma-a report from the German Cooperative Pediatric Liver Tumor Study HB-89[J]. J Pediatr Surg, 1995, 30(6): 845-852.
[13]
Fukuzawa H, Urushihara N, Fukumoto K, et al. Can we predict the prognosis of resectable hepatoblastoma from serum alpha-fetoprotein response during preoperative chemotherapy?[J]. Pediatr Surg Int, 2012, 28(9): 887-891.
2016, Vol. 27 
